Accelerate Diagnostics $AXDX Kits That Cut Blood Cultures Costs By 50%

On March 28, 2022, Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, announced the launch of the Accelerate Arc system, comprised of the Arc Module and BC Kit, an automated path to rapid and accurate microbial identification for positive blood cultures.

Designed for labs with MALDI, the Accelerate Arc Module is a novel application of inline centrifugal and sample preparation techniques, providing a suspension of cleaned and concentrated microbial cells, which together with the blood culture (BC) kit, allow for direct transfer to a MALDI spotting plate.

The simple load-and-go workflow eliminates the need for batching multiple specimen tests, cutting hours off the wait for microbial ID results for positive blood cultures. The Arc module requires just 2-3 minutes of hands-on time to run and is simple enough to be used on all shifts, by any laboratory technician.

In addition, the Accelerate Arc system is designed to eliminate the need for overnight culture incubation for current MALDI users, while reducing the likelihood of cross reactivity and potential false positive results that come with rapid multi-targeted molecular tests. For some labs, roughly 30% of molecular tests turn up as contaminants, increasing the number of expensive rapid multi-targeted molecular kits that are wasted.

“I am excited to be launching this new system as promised and with strong early performance data. The total cost to rapidly identify organisms from positive blood cultures could be at least fifty percent less than what you’re paying today for a rapid molecular ID solution,” said Jack Phillips, President, and CEO of Accelerate Diagnostics. “When you think of the extreme pressure that labs are under today, the Arc is a fast and inexpensive diagnostic tool which frees up valuable technician time by automating the MALDI workflow.

Recent studies conducted on the efficacy and time-saving benefits of the Arc study will be presented at the upcoming 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022). The Arc is currently intended for Research Use Only and is not for use in diagnostic procedures.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier. For more information about the company, its products and technology, or recent publications, visit htpps://axdx.com.

📺 Accelerate Diagnostics What It Means To Us

What the Accelerate Pheno System Means To Us

📉 AXDX Stock Technical Analysis

The positive divergence between large players volume and price is bullish; however, the short term trend is negative, as is the long term trend. AXDX is one of the lesser performing stocks in the Health Care Equipment & Supplies industry. 86% of 218 stocks in the same industry do better. AXDX is currently making a new 52 week low. This is a very bad signal. AXDX is lagging the S&P500 Index which is trading in the middle of its 52 week range. Prices have been falling strongly lately, it is better to avoid new long positions here.

There is resistance at 1.68 from a trend line in the daily time frame. There is also resistance at 2.14 from a trend line in the daily time frame. Finally, there is resistance at 2.22 from a trend line in the weekly time frame.

The technical rating of AXDX is bad and it also does not present a quality setup at the moment. AXDX stock has a Setup Rating of 3 out of 10. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when AXDX stock consolidates and has a Setup Rating of 8 or higher.

close

Don’t miss these catalysts!

We don’t spam! Read our privacy policy for more info.

Latest News

Sign up for our Free Daily Newsletter

Sample of the Daily Guerilla Stock Trading Newsletter

Guerilla Stock Trading